Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

March 16, 2023

Study Completion Date

March 16, 2023

Conditions

Sarcoma

Interventions

DRUG

Autologous CIK

Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)

Trial Locations (1)

AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita, Turin

All Listed Sponsors

lead

Prof. Franca Fagioli

OTHER

NCT04802070 - Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment. | Biotech Hunter | Biotech Hunter